Norway· NO-ID_B057DACF-C3F4-4670-A613-4F37F07714F7
Feiba
A faktor viii-inhibitor bypass aktivität - feiba product containing factor viii inhibitor bypassing fraction, registered in Norway by Baxalta Innovations GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Faktor viii-inhibitor bypass aktivität - feiba is registered in 10 of 19 countries.
Countries holding a registration under ATC B02BD03 (faktor viii-inhibitor bypass aktivität - feiba), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 6 of them publish a price we can compare per daily dose
Faktor viii-inhibitor bypass aktivität - feiba · ATC B02BD03
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Factor Viii Inhibitor Bypassing Fraction
- Manufacturer
- Baxalta Innovations GmbH
- Country
- Norway (NO)
- ATC code
- B02BD03
- ATC class
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBA
- Defined daily dose
- 7 TSD, E
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- gtin7038319162440
- no_varenummer5054941NOK 10259.4
- no_merkevare_idID_B057DACF-C3F4-4670-A613-4F37F07714F7
- no_varenummer4664761NOK 25594.2
- gtin7038319162433
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for faktor viii-inhibitor bypass aktivität - feiba.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Faktor viii-inhibitor bypass aktivität - feiba · interactions on record
5 records
- 4 severe
- 1 moderate
Most severe, free to view
- Aminocaproic acidB02AA01severe
- Tranexamic acidB02AA02severe
- AprotininB02AB01severe
- EmicizumabB02BX06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Faktor viii-inhibitor bypass aktivität - feiba in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFEIBA 100units/ml (1,000unit) powder and 10ml solvent for solution for infusion vialsTakeda UK Ltd
- FinlandFeibaBaxalta Innovations GmbH
- SwedenFeiba 100 E/ml Pulver och vätska till infusionsvätska, lösningBaxalta Innovations GmbH
- CanadaFEIBA NFTAKEDA CANADA INC
- IrelandFEIBA 100 U/ml powder and solvent for solution for infusionBaxalta Innovations GmbH
- BelgiumFeiba 1000 UBaxalta Innovations
- GermanyFeibaTakeda Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Feiba
- Belgium · Feiba
- Bulgaria · Фейба
- Cyprus · Feiba
- Czechia · Feiba
- Germany · Feiba
- Denmark · Feiba
- Estonia · Feiba
- Spain · Feiba
- Finland · Feiba
- France · Feiba
- United Kingdom (Northern Ireland) · Feiba
- Greece · Feiba
- Croatia · Feiba
- Hungary · Feiba Nf
- Ireland · Feiba
- Italy · Feiba
- Lithuania · Feiba
- Latvia · Feiba
- Malta · Feiba
- Netherlands · Feiba
- Poland · Feiba Nf
- Portugal · Feiba Nf
- Romania · Feiba
- Sweden · Feiba
- Slovenia · Feiba
- Slovakia · Feiba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9bc66035-bbc0-4925-8991-62fafc9e2244 GET /v1/drugs/9bc66035-bbc0-4925-8991-62fafc9e2244?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver og væske til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Faktor VIII-inhibitor bypass-aktivitet",
"merkevare_id": "ID_B057DACF-C3F4-4670-A613-4F37F07714F7",
"name_form_strength": "Feiba pulv+væske til inf oppl 100 E/ml",
"prescription_group": "C"
}See everything about faktor viii-inhibitor bypass aktivität - feiba.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.